Evidence map›Paper›PMID 30305383›Full record

ArticleJournal of clinical microbiology2018

Limited Marginal Utility of Deep Sequencing for HIV Drug Resistance Testing in the Age of Integrase Inhibitors.

Ronit R Dalmat, Negar Makhsous, Gregory G Pepper, Amalia Magaret, Keith R Jerome, Anna Wald, Alexander L Greninger

Abstract readComparative Study
In one paragraph

Article in Journal of clinical microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Practical updates in clinical antiviral resistance testing.Journal of clinical microbiology · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. MiDRMViruses · 2019
    Article
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ronit R DalmatDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Negar MakhsousDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Gregory G PepperDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Amalia MagaretDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Keith R JeromeDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA.
Anna WaldDepartment of Epidemiology, University of Washington, Seattle, Washington, USA.
Alexander L GreningerDepartment of Laboratory Medicine, University of Washington, Seattle, Washington, USA agrening@uw.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HIV drug resistance genotyping is a critical tool in the clinical management of HIV infections. Although resistance genotyping has traditionally been conducted using Sanger sequencing, next-generation sequencing (NGS) is emerging as a powerful tool due to its ability to detect low-frequency alleles. However, the clinical value added from NGS approaches to antiviral resistance testing remains to be demonstrated. We compared the variant detection capacity of NGS versus Sanger sequencing methods for resistance genotyping in 144 drug resistance tests (105 protease-reverse transcriptase tests and 39 integrase tests) submitted to our clinical virology laboratory over a four-month period in 2016 for Sanger-based HIV drug resistance testing. NGS detected all true high-frequency drug resistance mutations (>20% frequency) found by Sanger sequencing, with greater accuracy in one instance of a Sanger-detected false positive. Freely available online NGS variant callers HyDRA and PASeq were superior to Sanger methods for interpretations of allele linkage and automated variant calling. NGS additionally detected low-frequency mutations (1 to 20% frequency) associated with higher levels of drug resistance in 30/105 (29%) protease-reverse transcriptase tests and 4/39 (10%) integrase tests. In clinical follow-up of 69 individuals for a median of 674 days, we did not find a difference in rates of virological failure between individuals with and without low-frequency mutations, although rates of virological failure were higher for individuals with drug-relevant low-frequency mutations. However, all 27 individuals who experienced virological failure reported poor adherence to their drug regimen during the preceding follow-up time, and all 19 who subsequently improved their adherence achieved viral suppression at later time points, consistent with a lack of clinical resistance. In conclusion, in a population with low antiviral resistance emergence, NGS methods detected numerous instances of minor alleles that did not result in subsequent bona fide virological failure due to antiviral resistance.

Indexed as

High-Throughput Nucleotide SequencingSequence Analysis, RNAAdolescentAdultAgedChildChild, PreschoolDatabases, GeneticDrug MonitoringDrug Resistance, ViralFemaleGenotypeHIVHIV InfectionsHIV Integrase InhibitorsHIV Protease InhibitorsHIV Integrase InhibitorsHIV Protease InhibitorsRNA, ViralAIDSamplicon sequencingantiretroviralantiviral resistancedeep sequencingHIVHyDRAnext-generation sequencingPASeqresistance

Identifiers

PMID30305383
PMCPMC6258839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.